PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
34077739-1	2021	We performed additional mechanistic analyses to redefine neratinib biology and determined the mechanisms by which the multi-kinase inhibitor neratinib interacted with the thymidylate synthase inhibitor pemetrexed to kill NSCLC cells expressing either mutant KRAS (G12S; Q61H; G12A; G12C) or mutant NRAS (Q61K) or mutant ERBB1 (L858R; L858R T790M; exon 19 deletion).	neratinib	141-150	thymidylate synthetase	Homo sapiens	171-191	
34077739-1	2021	We performed additional mechanistic analyses to redefine neratinib biology and determined the mechanisms by which the multi-kinase inhibitor neratinib interacted with the thymidylate synthase inhibitor pemetrexed to kill NSCLC cells expressing either mutant KRAS (G12S; Q61H; G12A; G12C) or mutant NRAS (Q61K) or mutant ERBB1 (L858R; L858R T790M; exon 19 deletion).	neratinib	141-150	KRAS proto-oncogene, GTPase	Homo sapiens	258-262	
34077739-1	2021	We performed additional mechanistic analyses to redefine neratinib biology and determined the mechanisms by which the multi-kinase inhibitor neratinib interacted with the thymidylate synthase inhibitor pemetrexed to kill NSCLC cells expressing either mutant KRAS (G12S; Q61H; G12A; G12C) or mutant NRAS (Q61K) or mutant ERBB1 (L858R; L858R T790M; exon 19 deletion).	neratinib	141-150	NRAS proto-oncogene, GTPase	Homo sapiens	298-302	
34077739-1	2021	We performed additional mechanistic analyses to redefine neratinib biology and determined the mechanisms by which the multi-kinase inhibitor neratinib interacted with the thymidylate synthase inhibitor pemetrexed to kill NSCLC cells expressing either mutant KRAS (G12S; Q61H; G12A; G12C) or mutant NRAS (Q61K) or mutant ERBB1 (L858R; L858R T790M; exon 19 deletion).	neratinib	141-150	epidermal growth factor receptor	Homo sapiens	320-325	
34077739-2	2021	Neratinib rapidly reduced KRASG12V and RAC1G12V nanoclustering which was followed by KRASG12V, but not RAC1G12V, being extensively mislocalized away from the plasma membrane.	neratinib	0-9	Rac family small GTPase 1	Homo sapiens	39-43	
34077739-7	2021	Compared to osimertinib-resistant cells, sensitive cells had less ERBB2 Y1248 phosphorylation.	osimertinib	12-23	erb-b2 receptor tyrosine kinase 2	Homo sapiens	66-71	
34077739-7	2021	Compared to osimertinib-resistant cells, sensitive cells had less ERBB2 Y1248 phosphorylation.	4-Bromo-2-cyanobenzoic acid	72-77	erb-b2 receptor tyrosine kinase 2	Homo sapiens	66-71	
34077739-8	2021	In osimertinib resistant H1975 cells, the drug combination was less capable of inactivating AKT, mTOR, STAT3, STAT5, ERK1/2 whereas it gained the ability to inactivate ERBB3.	osimertinib	3-14	AKT serine/threonine kinase 1	Homo sapiens	92-95	
34077739-8	2021	In osimertinib resistant H1975 cells, the drug combination was less capable of inactivating AKT, mTOR, STAT3, STAT5, ERK1/2 whereas it gained the ability to inactivate ERBB3.	osimertinib	3-14	mechanistic target of rapamycin kinase	Homo sapiens	97-101	
34077739-8	2021	In osimertinib resistant H1975 cells, the drug combination was less capable of inactivating AKT, mTOR, STAT3, STAT5, ERK1/2 whereas it gained the ability to inactivate ERBB3.	osimertinib	3-14	signal transducer and activator of transcription 3	Homo sapiens	103-108	
34077739-8	2021	In osimertinib resistant H1975 cells, the drug combination was less capable of inactivating AKT, mTOR, STAT3, STAT5, ERK1/2 whereas it gained the ability to inactivate ERBB3.	osimertinib	3-14	signal transducer and activator of transcription 5A	Homo sapiens	110-115	
34077739-8	2021	In osimertinib resistant H1975 cells, the drug combination was less capable of inactivating AKT, mTOR, STAT3, STAT5, ERK1/2 whereas it gained the ability to inactivate ERBB3.	osimertinib	3-14	mitogen-activated protein kinase 3	Homo sapiens	117-123	
34077739-8	2021	In osimertinib resistant H1975 cells, the drug combination was less capable of inactivating AKT, mTOR, STAT3, STAT5, ERK1/2 whereas it gained the ability to inactivate ERBB3.	osimertinib	3-14	erb-b2 receptor tyrosine kinase 3	Homo sapiens	168-173	
34077739-12	2021	(Neratinib + pemetrexed) increased phosphorylation of YAP and TAZ, caused their nuclear exit, and enhanced ERBB2 degradation.	neratinib	1-10	Yes1 associated transcriptional regulator	Homo sapiens	54-57	
34077739-12	2021	(Neratinib + pemetrexed) increased phosphorylation of YAP and TAZ, caused their nuclear exit, and enhanced ERBB2 degradation.	neratinib	1-10	tafazzin, phospholipid-lysophospholipid transacylase	Homo sapiens	62-65	
34077739-12	2021	(Neratinib + pemetrexed) increased phosphorylation of YAP and TAZ, caused their nuclear exit, and enhanced ERBB2 degradation.	neratinib	1-10	erb-b2 receptor tyrosine kinase 2	Homo sapiens	107-112	
34077739-12	2021	(Neratinib + pemetrexed) increased phosphorylation of YAP and TAZ, caused their nuclear exit, and enhanced ERBB2 degradation.	Pemetrexed	13-23	Yes1 associated transcriptional regulator	Homo sapiens	54-57	
34077739-12	2021	(Neratinib + pemetrexed) increased phosphorylation of YAP and TAZ, caused their nuclear exit, and enhanced ERBB2 degradation.	Pemetrexed	13-23	tafazzin, phospholipid-lysophospholipid transacylase	Homo sapiens	62-65	
34077739-12	2021	(Neratinib + pemetrexed) increased phosphorylation of YAP and TAZ, caused their nuclear exit, and enhanced ERBB2 degradation.	Pemetrexed	13-23	erb-b2 receptor tyrosine kinase 2	Homo sapiens	107-112